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Venselaar H, Vriend G, Lee WH, Park HJ, Kwon TK, Bok J, Kim
UK. Clinical and molecular characterizations of novel POU3F4
mutations reveal that DFN3 is due to null function of POU3F4
protein. Physiol Genomics 39: 195–201, 2009. First published August
11, 2009; doi:10.1152/physiolgenomics.00100.2009.—X-linked deaf-
ness type 3 (DFN3), the most prevalent X-linked form of hereditary
deafness, is caused by mutations in the POU3F4 locus, which encodes a
member of the POU family of transcription factors. Despite numerous
reports on clinical evaluations and genetic analyses describing novel
POU3F4 mutations, little is known about how such mutations affect
normal functions of the POU3F4 protein and cause inner ear malforma-
tions and deafness. Here we describe three novel mutations of the
POU3F4 gene and their clinical characterizations in three Korean fami-
lies carrying deafness segregating at the DFN3 locus. The three mutations
cause a substitution (p.Arg329Pro) or a deletion (p.Ser310del) of highly
conserved amino acid residues in the POU homeodomain or a truncation
that eliminates both DNA-binding domains (p.Ala116fs). In an attempt to
better understand the molecular mechanisms underlying their inner ear
defects, we examined the behavior of the normal and mutant forms of the
POU3F4 protein in C3H/10T1/2 mesodermal cells. Protein modeling as
well as in vitro assays demonstrated that these mutations are detrimental
to the tertiary structure of the POU3F4 protein and severely affect its
ability to bind DNA. All three mutated POU3F4 proteins failed to
transactivate expression of a reporter gene. In addition, all three failed to
inhibit the transcriptional activity of wild-type proteins when both wild-
type and mutant proteins were coexpressed. Since most of the mutations
reported for DFN3 thus far are associated with regions that encode the
DNA binding domains of POU3F4, our results strongly suggest that the
deafness in DFN3 patients is largely due to the null function of POU3F4.
hearing loss; X-linked deafness type 3; inner ear
CONGENITAL HEARING LOSS IS one of the most common sensory
disorders in humans, affecting approximately one in 1,000 new-
borns (24). More than 50% of the congenital hearing loss is due to
genetic causes, and the majority of these hereditary cases are
nonsyndromic. While most genetic nonsyndromic hearing loss is
caused by mutations in autosomal genes, X-linked cases are
estimated to comprise between 1 and 5% of these (26). Thus far,
four different X-linked nonsyndromic hearing loss loci (DFN2,
DFN3, DFN4, and DFN6) have been mapped, but the causative
gene has been identified only for the DFN3 locus (33).
X-linked deafness type 3 (DFN3) accounts for 50% of all
families carrying X-linked nonsyndromic hearing loss (26).
Clinical characteristics of DFN3 in affected males include
temporal bone abnormalities, stapes fixation, and, in most
cases, a mixed type of hearing loss, which is often progressive
(7, 8, 10). Anatomical anomalies of the temporal bone revealed
by computer-assisted tomography (CT) include dilatation of
the lateral end of the internal acoustic canal (IAC), abnormally
wide communication between the IAC and inner ear compart-
ment, and, sometimes, partial hypoplasia of the cochlea (8, 27).
As a result of the widening of the bony IAC, cerebrospinal
fluid can enter the vestibule, which is thought to underlie the
reported “gusher” phenomenon, described as fluid gushing out
upon removal of the stapes footplate during corrective surgery
(8). Female carriers of a mutation in the DFN3 locus typically
show little or no hearing loss (26).
Deafness segregating at the DFN3 locus is associated with
mutations in the POU3F4 gene (11). POU3F4 belongs to a
superfamily of POU domain transcription factors, which are
characterized by a conserved bipartite DNA binding domain.
This domain consists of a POU-specific domain and a POU
homeodomain, both of which are helix-turn-helix structural
motifs that influence DNA binding and specificity (22). Studies
using POU3F4 murine ortholog (Brn-4/Pou3f4) showed that
the Pou3f4 protein binds to DNA on the POU-specific binding
motif and regulates downstream target genes (22). Expression
of Pou3f4 is found broadly in the developing neural tube
during embryogenesis but is restricted to the forebrain in adults
(20, 22). Pou3f4 has also been shown to be expressed in the
limb muscle, pancreas, and inner ear (12, 17, 28, 29). During
inner ear development, Pou3f4 expression is exclusively de-
tected in the mesenchymal tissue adjacent to the otic epithe-
lium (28, 29). Targeted deletion of Pou3f4 in mice results in
abnormalities mainly in the mesenchyme-derived structures
such as the spiral limbus, the scala tympani, and strial fibro-
cytes of the cochlea, as well as defects in the temporal bone
(23, 29). In addition, Pou3f4 knockout mice also display
malformations in tissues that do not normally express Pou3f4
such as the stapes of the middle ear and the membranous
components of the cochlea, indicating possible roles of Pou3f4
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in reciprocal interactions between peri-otic mesenchyme and
other tissues such as the otic epithelium (29).
Numerous genetic analyses of DFN3 families have identified
mutations in the POU3F4 gene. These include intragenic muta-
tions, partial or complete deletions of the gene, as well as dele-
tions, inversions, and duplications of the POU3F4 genomic
region not encompassing the POU3F4 coding sequence (8).
Clinical characterizations of affected individuals and their
specific mutations in POU3F4 have also been described (8).
Nevertheless, little is known about how such mutations affect
the normal function of the POU3F4 protein, which leads to the
characteristic inner ear defects and deafness. Nor is it known
how POU3F4 contributes to the normal development of the
inner ear.
Here we report three novel mutations in the POU3F4 gene
identified in three Korean families carrying X-linked hereditary
hearing loss and the clinical characterization of affected family
members. In addition, we performed molecular modeling and
various in vitro assays to understand the molecular basis of the
inner ear defects caused by these mutations.
MATERIALS AND METHODS
Subjects and clinical evaluations. Two Korean families exhibiting an
X-linked inheritance pattern and one Korean family in which X-linked
inheritance was plausible were ascertained at the Department of Otorhi-
nolaryngology, Yonsei University College of Medicine, Seoul, South
Korea. The proband of each family was subjected to detailed clinical
evaluations including medical history, otologic examinations, audiologic
testing, and CT of the temporal bone. The clinical evaluations were also
performed on other members of the families, including affected males
and the female carriers. For audiologic testing, either brainstem-evoked
response audiometry (BERA) or pure tone audiometry (PTA) was per-
formed in line with the age of the patient, and the pure tone average was
calculated with the thresholds at 0.5, 1, 2, and 4 kHz. High-resolution
temporal bone CT was performed with a 16 row multi-detector CT
scanner (SOMATOM Sensation 16; Siemens, Erlangen, Germany) by
using a standard temporal bone protocol (18). Contiguous 0.7-mm scans of
the temporal bone were acquired in the axial plane and reformatted coronally
with 1.0-mm increments. Written informed consent was obtained from
participating individuals, and this study was approved by the Institutional
Review Board of the Yonsei University College of Medicine.
Genetic analyses. For linkage analyses, genomic DNAs from the
families were extracted from peripheral blood using the FlexiGene DNA
extraction kit (Qiagen). They were genotyped with centromeric micro-
satellite marker DXS986 (57.36 cM from Marshfield Map) and telomeric
maker DXS6803 (57.91 cM from Marshfield Map) flanking the DFN3
locus (Xq21.1) using standard PCR conditions. The coding region of
POU3F4 was amplified for direct sequencing using three sets of primers:
1) forward primer 5-GTAACCCGTGCTAGCGTCTT-3 and reverse
primer 5-GTCGGAGTGATCCTGGCAAT-3, 2) forward primer 5-
CACTCACCGCACACTAACCA-3 and reverse primer 5-ACACG-
CACCACTTCCTTCTC-3, 3) forward primer 5-CTCCATCGAGGT-
GAGTGTCA-3 and reverse primer 5-GGAGCCAGGAATAT-
GAGATCC-3. The amplified DNA fragments were sequenced with an
ABI PRISM Big Dye Terminator Cycle Sequencing Kit (V3.1) and an
ABI PRISM 3130XL DNA analyzer (Applied Biosystems). Data were
analyzed by using ABI Sequencing Analysis (v.5.0) and Lasergene-
SeqMan software. The resulting sequences were compared with the
POU3F4 sequence from GenBank (accession no. NM_000307). We also
sequenced 70 Koreans with normal hearing to determine whether the
mutations were presented in the unaffected Korean population.
Molecular modeling. The crystal structure of POU2F1/Oct-1 was
used as a template to build a model of wild-type and mutant POU3F4
proteins. Modeling was performed with the WHAT IF software (34)
with standard parameter settings and protocols as described previ-
ously (4, 9). The details of the modeling protocol, including files used,
sequence alignment, parameter choices, etc., are available from http://
www.cmbi.ru.nl/hvensela/pou3f4/.
Plasmid construction. To construct expression vectors for wild-
type and mutant POU3F4 proteins, the full-length open reading frame
(ORF) of the single-exon POU3F4 gene was amplified by PCR from
the genomic DNA of normal or affected males and sub-cloned into the
pcDNA3 expression vector. The primer pairs used were 5-atgaattcat-
ggccacagctgcctcg-3 and 5-atgcggccgctcagagatcatggcaag-3. Oligo-
nucleotides encoding the hemagglutinin (HA) epitope were also
inserted at the 5 of the POU3F4 ORF.
Immunocytochemistry. C3H10T1/2 cells grown on a LabTek 8 cham-
ber slide were transfected with either wild-type or mutant POU3F4
expression plasmids, together with EGFP plasmid. Forty-eight hours
later, the cells were fixed with 4% paraformaldehyde for 10 min and
permeabilized by 0.5% Triton for 10 min at room temperature. The cells
were then incubated sequentially with monoclonal anti-HA antibody
(Zymed) overnight at 4°C, AlexaFluor 568 anti-mouse IgG antibody
(Invitrogen) for 1 h at room temperature, and 4, 6-diamidino-2-
phenylindole for 5 min at room temperature. Images of the immuno-
stained cells were taken with Olympus IX70 fluorescent microscope
equipped with Olympus DP70 camera (Zeiss) and processed using
Adobe Photoshop (Adobe Systems). To determine the percentages of the
cells expressing POU3F4 proteins outside the nucleus, 100–200 cells
from each chamber were counted manually by an investigator blind to the
sample identities. Graphs were plotted based on the numbers collected
from at least three independent experiments.
Expression and purification of recombinant POU3F4 protein. A
glutathione S-transferase (GST) recombinant POU3F4 plasmid was
constructed by subcloning the digested fragment containing whole
POU3F4 sequences into pGEX-4T-1 KpnI/EcoRI site. GST fusion
proteins were purified from the respective Escherichia coli BL21
extracts with glutathione-Sepharose (Pharmacia, Piscataway, NJ) ac-
cording to standard procedures (14).
Electrophoretic mobility shift assay. The sequences of the double-
stranded oligonucleotides used to detect the DNA-binding activi-
ties of POU3F4 were as follows: 5-CAATATGCTAATCAATAT-
GCTAAT-3. The reaction mixture for electrophoretic mobility
shift assay (EMSA) contained 20 mM Tris  HCl, pH 7.6, 1 mM
dithiothreitol, 2 mM MgCl2, 1 mM EDTA, 10% glycerol, 1%
NP-40, 1 g poly(dI-dC), and 2 g purified recombinant GST-
POU3F4 fusion proteins. Unlabeled oligonucleotides were added
into the reaction mixture and incubated for 10 min at room
temperature. [32P]-labeled probe DNA (300,000 cpm) was added,
and the binding reaction was allowed to proceed for another 20
min. Mixtures were resolved on 8% polyacrylamide gels at 150 V
for 4 h. Gels were dried and subjected to autoradiography.
Transcription reporter assays. The luciferase reporter plasmids were
constructed by inserting either the upstream promoter region of human
POU3F4 gene (482 to 25), or two or three copies of the Pou3f4
binding element (CAATATGCTAAT) into the pGL2 basic vector (21).
C3H10T1/2 cells plated in 24-well plates were cotransfected with 300 ng
of either wild-type or mutant POU3F4 expression plasmid, or both
plasmids together, 150 ng of the luciferase reporter plasmid, and 20 ng of
SV40-renilla plasmid for the transfection efficiency control. The trans-
fected cells were incubated for 24 h and subjected to the luciferase assay
according to the manufacturer’s protocol (Promega). Transfection effi-
ciencies in each condition were normalized with renilla luciferase activ-
ity, which was under the control of a SV-40 promoter. Results were
plotted based on at least three independent experiments.
RESULTS
Clinical characterizations of families carrying X-linked deaf-
ness. The pedigree of family SV08-18 showed a typical X-
linked recessive inheritance pattern of hearing loss (Fig. 1A).
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PTA measurements indicated that the proband of this family
(IV-2, 6 yr) had a severe mixed type of hearing loss (Fig. 1B).
Three other affected older males (III-3, 36 yr; III-6, 29 yr;
III-7, 16 yr) also showed similar patterns of hearing loss, but
the thresholds were higher than that of the proband (Fig. 1B).
Although longitudinal data on hearing loss were not available
for these male family members, more severe hearing loss
shown in older males especially in the sensorineural compo-
nent suggested progressiveness of hearing impairment, as pre-
viously reported (8). Two female carriers in the family (III-2,
III-4) had normal hearing (Fig. 1B).
The second family, SV08-17, also showed a typical X-linked
recessive inheritance pattern of hearing loss: five males being
affected in three generations (Suppl. Fig. S1).1 The proband
was diagnosed with severe hearing loss by BERA [thresholds
60 dB nHL (decibel normal hearing level)] 1 mo after birth
and is in the process of auditory rehabilitation with hearing
aids. Another affected male in the family (II-4, 23 yr) was also
diagnosed with hearing loss at the age of 6 yr and developed
only limited verbal communication with hearing aids.
In the third family, SV08-21, the proband was diagnosed
with severe hearing loss by BERA (75 and 90 dB nHL on the
right and left side, respectively) at the age of 2 yr (Suppl. Fig.
S1). Audiologic testing was not available for other members of
the family, although the granduncle of the proband had sus-
pected hearing loss. Since the proband and his mother carried
the same mutation, the hearing loss appeared to be inherited in
an X-linked recessive pattern in this family (Fig. 2; data not
shown).
Further CT scans performed on six patients from all three
families revealed that the defects of the temporal bones were
comparable for all the patients examined and were character-
istic of DFN3 (8, 27), including a wide fistulous connection
between the basal turn of the cochlea and the IAC, and defects
in the cochlear modiolus (Fig. 1C; data not shown). No other
medical or neurological deficits were identified in any of the
affected family members.
Linkage and mutation analyses. Since the family histories
and clinical evaluations of all three families were characteristic
for DFN3, we performed linkage analyses using DXS986 and
DXS6803 microsatellite markers. Deafness showed linkage to
the DFN3 locus in these families (Suppl. Fig. S1), so we
searched for mutations in the POU3F4 gene in the affected
members of the families by directly sequencing the POU3F4
coding region. Sequence analyses in family SV08-18 re-
vealed a point mutation at nucleotide 986, guanine to
cytosine (c.986 GC) (Fig. 2A). This nucleotide change
converts an arginine to a proline at the amino acid position
329 (p.R329P), which is one of the most conserved residues
in the POU homeodomain of the POU3F4 protein (Fig. 2E).
Sequence analyses of family SV08-17 identified a one-base
pair (bp) deletion at nucleotide position 346 (c.346delG) (Fig.
2B). This mutation causes a frame shift that encodes 25 new
amino acids followed by premature termination of the protein
at amino acid position 141 (p.Ala116fs). This results in a
truncated form of the POU3F4 protein lacking both DNA
binding domains (Fig. 2D).
The affected members of family SV08-21 had an in-frame
deletion of three nucleotides (c.927-929delCTC; Fig. 2C),
resulting in a deletion of the amino acid serine (p.S310del) in
the POU homeodomain (Fig. 2C).
Structural analyses of the wild-type and mutant POU3F4
proteins. The POU3F4 protein consists of an NH2-terminal
domain important for transcriptional activity and two COOH-
terminal DNA-binding domains. These DNA-binding domains
consist of the POU-specific domain connected by a short linker
region to the POU homeodomain (13, 20, 22) (Fig. 2D). All
three mutations identified in this study were expected to affect
DNA binding activity of the POU3F4 protein, because they affect
one of these domains. To examine the effect of the mutations on1 The online version of this article contains supplemental material.
Fig. 1. Clinical characterizations of the family SV08-18 showing X-linked hereditary hearing loss. A: pedigree showing a typical X-linked recessive inheritance
pattern of hearing loss. Square (male), circle (female), shaded (affected individual), slashed (deceased), circle with a dot (female mutation carrier), arrow (the
proband of the family). B: audiograms of the proband (IV-2, 6 yr) with a severe mixed hearing loss and older male members with worse hearing are shown. A
female carrier (III-4, 32 yr) shows normal hearing. E (right)  (left): air conduction threshold.  (right)  (left): bone conduction threshold. dBHL, decibel
hearing level. C: high resolution computer-assisted tomographic (CT) scans of the temporal bones of the proband (IV-2) shows characteristic findings of X-linked
deafness type 3 (DFN3) such as fistulous connection between the basal turn of cochlea and internal auditory canal and defective cochlear modiolus (left panel,
arrowhead), unlike the normal appearance of cochlear modiolus in the normal temporal bone (right panel, arrow).
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the tertiary structure of the POU3F4 protein, molecular mod-
els of wild-type, p.R329P, and p.S310del POU3F4 proteins
were built based on the known crystal structure of the
POU2F1/Oct-1 protein (19).
The p.R329P mutation is located in the third 	-helix of the
POU homeodomain, which is crucial for protein-DNA inter-
actions (Fig. 2, E–G). The substitution of proline for the
normal arginine at this position is expected to be detrimental to
the 	-helix structure due to destabilization of two important
salt-bridges as well as loss of a series of hydrophobic contacts.
In addition, the amino acid side chain structure of proline
typically inserts an obligate bend that disrupts 	-helical struc-
tures. Such disturbances generally tend to massively reduce the
proper protein-DNA interactions.
The serine residue at position 310 is located in the middle of
the second 	-helix of the POU homeodomain (Fig. 2E). This
helix is not in direct contact with the DNA but is likely
important for the overall structure of the POU homeodomain.
The homology model suggests that 	-helical structure will
remain after deletion of the serine residue (p.S310del) (Fig.
2H). However, since the absence of one residue will cause a
shift of one position for the subsequent residues in this helix,
this will have dramatic effects on the stability of this helix
because several hydrophobic interactions will get lost and a
polar residue will become buried in the hydrophobic core of the
protein. As a result, the interaction with the other helices is
disturbed and the overall stability of the domain is decreased,
which will severely reduce its DNA binding ability.
Fig. 2. Three novel mutations in POU3F4 locus are
expected to affect protein-DNA interaction of
POU3F4 protein. A–C: novel mutations identified in
3 Korean families carrying X-linked hereditary deaf-
ness. A: family SV08-18 carries a mutation of G to
C at nucleotide position 986, which results in a
conversion of arginine to proline at the amino acid
position 329 (p.R329P). This G-to-C change is ob-
served in all affected males, and G/C heterozygosity
was detected in all female carriers. B: a 1 bp deletion
identified in family SV08-17 causes a frame shift of
26 amino acids starting from alanine at the amino
acid position 116, followed by a truncation
(p.Ala116fs). C: a deletion of 3 nucleotides from
position 927 to 929 detected in family SV08-21
causes a single amino acid deletion (p.S310del)
without affecting the coding frame. D: schematic
illustration of POU3F4 protein labeled with the 3
novel mutations identified in this study. POU-
specific and homeodomain are shown as red and
blue boxes, respectively, and 3 putative nuclear
localization signals (NLS) are indicated as yellow
boxes above the POU-specific or POU homeodo-
main. The positions of the mutation are indicated
with arrows, and the location of premature termina-
tion in p.Ala116fs mutation is marked by an asterisk.
p.R329P mutation is located in one of the putative
NLSs in the POU homeodomain. E: alignment of the
amino acid sequence of the 2nd and 3rd 	-helices in
the POU3F4 proteins from several eukaryotes.
Amino acid sequence in this region is highly con-
served in mammals. F–H: molecular modeling of
the wild-type and mutant POU3F4 proteins. F: the
3rd helix in the POU homeodomain is illustrated.
The green amino acid residue is Arg329. DNA is
shown in a yellow ball-and-stick representation.
G: p.R329P mutation located in the 3rd 	-helix of
the POU homeodomain is expected to destabilize
the helical structure, affecting the proper protein-
DNA interactions. The 2 glutamates that had an
interaction with the lost arginine are shown, as is
the asparagine that makes important, specificity-
relating DNA contacts. H: in the p.S310del mu-
tant, the lack of one amino acid residue will cause
a shift of one position for all subsequent residues,
disrupting normal interactions. The details of the
modeling are also available from http://www.
cmbi.ru.nl/hvensela/pou3f4/.
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Effects of the POU3F4 mutations on DNA binding activity.
Our modeling study suggested that all three mutations identi-
fied in DFN3 patients are likely affecting DNA binding ability
by altering the tertiary structure of the DNA binding domains
of the POU3F4 protein. To test this possibility, we conducted
EMSA. Expression vectors encoding wild-type and mutant
forms of POU3F4 protein were constructed, and the proteins
were translated in vitro. The DNA-binding abilities of the
in vitro translated and purified POU3F4 proteins were tested
with the oligonucleotide probe (CAATATGCTAAT) that has
been shown to specifically bind the murine Pou3f4 proteins
(21). As shown in Fig. 3A, wild-type POU3F4 proteins bound
strongly to the labeled oligonucleotides to form protein-DNA
complexes (Fig. 3A, arrow). Specificity of the protein-DNA
interaction was confirmed by competition experiments, in
which addition of unlabeled oligonucleotide probes completely
abolished the protein-DNA interactions. In contrast to the
wild-type POU3F4, no detectable protein-DNA complexes
were observed with any of the mutant forms of POU3F4. These
results indicate that the mutations severely compromise the
ability of the POU3F4 proteins to bind target DNA sequences.
Effects of the POU3F4 mutations on subcellular localiza-
tion. The computer program “predictNLS” (5) predicts three
putative nuclear localization signal (NLS) motifs in wild-type
POU3F4. One of these is located in the POU-specific domain
and the other two are in the POU homeodomain (Fig. 2D). The
p.R329P mutation is located in one of the NLS motifs in the
POU homeodomain, and the p.S310del mutation is located
between the two NLSs in the POU homeodomain (Fig. 2D).
The truncating mutation (p.Ala116fs) results in a protein that
does not have any of the NLS motifs due to the lack of the
DNA binding domains.
To determine how these mutations affect nuclear localiza-
tion of the POU3F4 proteins, expression vectors encoding
wild-type or mutant POU3F4 proteins fused with the HA
epitope were transiently expressed in the C3H10T1/2 cells
(30). We chose this mouse mesenchymal cell line since Pou3f4
is mainly expressed in the mesenchyme surrounding the de-
veloping inner ear (28). Immunofluorescent analyses using
anti-HA or anti-POU3F4 antibodies showed that wild-type
POU3F4 proteins were localized exclusively in the nuclei of
transfected cells (Fig. 3B; data not shown). In contrast, the
majority of p.R329P or p.Ala116fs POU3F4 proteins, in which
at least one NLS motif is disrupted, were found in both the
cytoplasm and the nucleus (Fig. 3B). Although we expected
normal nuclear localization for the p.S310del mutant, which
preserved all three putative NLS motifs, POU3F4 proteins with
this mutation also lost their normal subcellular localization and
were found throughout the cells. This mislocalization could be
due to the changes in the tertiary structure of the POU home-
odomain where the NLS domains reside.
Effects of the POU3F4 mutations on transcriptional activi-
ties. The inability of the mutant POU3F4 proteins to bind to the
target DNA sequence or to correctly localize in the nucleus
strongly suggested that the transcriptional activity of the mu-
tant POU3F4 proteins would also be severely compromised.
To test this, we constructed a reporter plasmid, in which
expression of the firefly luciferase gene is regulated by the
promoter region (from 472 to 25 bp) of the human
POU3F4 gene, which has been shown to be directly regulated
by the POU3F4 protein itself (21). The reporter plasmid was
cotransfected with the plasmid encoding either wild-type or
mutant POU3F4 into C3H10T1/2 cells, and the ability of each
POU3F4 protein to transactivate the reporter gene was assessed
Fig. 3. DNA-binding ability and subcellular
localization were disrupted by the POU3F4
mutations. A: electrophoretic mobility shift
assay (EMSA). Wild-type POU3F4 proteins
formed a protein-DNA complex with the
labeled oligonucleotides (lane 3, arrow),
which were completely disrupted by adding
unlabeled oligonucleotides as competitors
(lanes 7, 8). In contrast, p.R329P (lane 4),
p.S310del (lane 5), or p.A116fs (lane 6)
mutant proteins failed to bind to the DNA
molecules. B: immunocytochemical analyses
with anti-hemagglutinin (HA) antibody of
wild-type and mutant POU3F4 proteins tran-
siently expressed in C3H10T1/2 cells. While
wild-type POU3F4 proteins were mostly lo-
calized inside the nucleus, most of the mu-
tant POU3F4 proteins were found in both the
nucleus and cytoplasm. C: graph quantifying
the percentage of cells expressing the POU3F4
proteins outside the nucleus.
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by measuring the luciferase activity in the transfected cells. In
this system, wild-type POU3F4 protein activated the reporter
gene expression almost threefold, but all three mutant POU3F4
proteins failed to activate the gene expression (Fig. 4B), indi-
cating that the POU3F4 mutations completely abolish the
transcriptional activity of POU3F4 proteins. Similar effects
were observed with another reporter construct whose luciferase
expression is under the control of two or three copies of the
POU3F4 recognition element (CAATATGCTAAT) (21) (data
not shown). Next, we tested to see if the mutant POU3F4 proteins
could act as dominant-interfering variants. When both wild-type
and any of the mutant POU3F4 proteins were coexpressed, the
reporter expression activated by wild-type POU3F4 protein was
not affected, indicating that the mutant POU3F4 proteins did not
inhibit normal transcriptional activity of wild-type proteins (Fig.
4B). These results demonstrate that the three mutations identified
in the DFN3 patients cause functional nulls of the POU3F4
protein.
DISCUSSION
We identified three novel mutations in the POU3F4 gene in
three Korean families displaying X-linked inheritance of hear-
ing loss. Two of the mutations (p.R329P and p.S310del) occur
in the POU homeodomain, and the third mutation (p.Ala116fs)
causes a premature termination, resulting in a protein lacking
the entire DNA-binding domains (Fig. 2). Like the three
mutations we have studied here, most of the POU3F4 muta-
tions identified in DFN3 patients specify amino acid changes in
regions that encode the DNA-binding domains, the majority
being in the POU homeodomain (8), suggesting that loss of
DNA binding ability may be a common pathological mecha-
nism at the molecular level. Indeed, protein modeling and
several molecular analyses demonstrate that the POU3F4 mu-
tations severely disrupt the DNA-binding ability of POU3F4,
thereby completely abolishing the transcriptional activity of the
protein (Figs. 3 and 4). The mutant POU3F4 proteins failed to
inhibit normal transcriptional activity of wild-type POU3F4,
excluding the possibility that the mutant proteins act as dominant-
interfering variants. Overexpression of the mutant POU3F4 pro-
teins in C3H10T1/2 cells did not seem to have any obvious
deleterious effects on normal cell behaviors such as cell prolifer-
ation or cell death (data not shown). Together, these observations
strongly suggest that the hearing loss in DFN3 is caused by the
loss of function of POU3F4 protein, rather than by gain of ectopic
functions of mutant proteins. Clinical evaluations of DFN3 pa-
tients in this study are consistent with previously published reports
that demonstrated no clear genotype-phenotype correlation be-
tween the different types of the POU3F4 mutations and the inner
ear (26).
Mutations in POU4F3, another POU domain transcription
factor, have been implicated in autosomal dominant hearing
loss DFNA15 (32). Similar to our POU3F4 results, molecular
analyses of POU4F3 mutations identified in DFNA15 patients
showed that the mutant POU4F3 proteins lack transcriptional
activity due to the loss of nuclear localization and DNA-
binding ability (6, 35). Thus, the two POU family transcription
factors share a common molecular pathological mechanism,
whereby transcription of target genes essential for inner ear
development is affected. Consistent with its expression in the
hair cells, POU4F3 has been shown to regulate genes important
for hair cell differentiation such as Gfi1 and Lhx3 (15, 16).
Similarly, the hearing loss in DFN3 by POU3F4 mutations is
most likely associated with lack of expression of downstream
target gene(s) that plays critical roles in inner ear development,
especially in the mesenchymal remodeling and otic epithelial-
mesenchymal interactions. Only a few target genes of POU3F4
have been identified to date in other tissues: proglucagon gene
in the 	-cells of the pancreas (17), D1A dopamine receptor
gene in the striatum (25), and human involucrin gene in the
epidermis (36). However, little is known about downstream
targets of POU3F4 in the peri-otic mesenchyme where Pou3f4
is actively expressed (28). The temporal bone CT scans of
DFN3 patients as well as the Pou3f4 knockout inner ear
phenotypes suggest that most of the inner ear malformations
were found in the structures derived from the mesenchyme (23,
28). Therefore, elucidating the downstream targets of POU3F4
in the peri-otic mesenchyme will be crucial to understand how
POU3F4 normally contributes to the mesenchymal patterning
in inner ear development.
While the genes regulated by POU3F4 are unclear, previous
studies provided hints as to how the POU3F4 gene is regulated
in the peri-otic mesenchyme during inner ear development.
TBX1, a member of the T-box gene family of transcription
factors and known causative gene for DiGeorge syndrome, is
expressed in both the otic epithelium and peri-otic mesen-
chyme (1). Studies using tissue-specific knockout mice suggest
that Tbx1 expressed in the mesenchyme is required for the
mesenchymal expression of Pou3f4 (1), although it is not clear
if Tbx1 directly regulates the mesenchymal Pou3f4 expression.
Consistent with this, a genetic interaction between Tbx1 and
Pou3f4 has been demonstrated to be necessary for normal
cochlear formation (3). Interestingly, expressions of both Tbx1
and Pou3f4 in the mesenchyme are dependent on Sonic hedge-
hog (31). Thus, a molecular pathway of Shh-Tbx1-Pou3f4 in
Fig. 4. Transcriptional activity of POU3F4 was abolished by
the POU3F4 mutations. A: luciferase activities in cells cotrans-
fected with various POU3F4 proteins and the promoter-absent
reporter construct. No luciferase activity was observed in cells
expressing either wild-type or mutant POU3F4 proteins.
B: luciferase activities in cells cotransfected with the reporter
construct containing the POU3F4 promoter region (from 472
to 25 bp) and various forms of POU3F4 proteins. Wild-type
POU3F4 protein upregulated the reporter gene expression,
while none of the mutant POU3F4 proteins did. Cotransfection
of the wild-type and any of the mutants induced luciferase
activities comparable to the level activated by the wild type
alone. *Significantly different from wild type (t-test, P 
0.001); #not significantly different from wild type (P  0.1).
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the peri-otic mesenchyme has been proposed to be involved in
the normal cochlear patterning (2). Further analyses of the
molecular networks regulating POU3F4 as well as downstream
genes regulated by POU3F4 are warranted to produce a better
understanding of the roles of POU3F4 in normal inner ear
patterning, as well as the causative mechanism of DFN3.
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